Sort   by:  
 Page size 
UnknownBRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Not available
S-EPMC6286161 | biostudies-literature
UnknownSurvival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Not available
S-EPMC4517051 | biostudies-literature
UnknownSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Not available
S-EPMC4811023 | biostudies-literature
UnknownRandomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Not available
S-EPMC6075852 | biostudies-literature
UnknownAcquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Not available
S-SCDT-10_1038-S44319-024-00333-0 | biostudies-other
UnknownManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Not available
S-EPMC6481621 | biostudies-literature
Sort   by:  
 Page size